Endovastec(SH:688016) Xin Lang Cai Jing·2025-10-10 10:28Core Viewpoint - Shanghai MicroPort CardioFlow Medtech Co., Ltd. announced an adjustment to the upper limit of the share repurchase price following the implementation of the 2025 semi-annual profit distribution plan [1] Summary by Sections Price Adjustment Details - The upper limit of the repurchase price was adjusted from 178.01 CNY per share to 176.73 CNY per share, effective from October 17, 2025 [2][5] Share Repurchase Overview - On October 28, 2024, the company’s board approved a second phase of share repurchase through centralized bidding, with a repurchase price not exceeding 180 CNY per share and a total repurchase fund between 100 million CNY and 200 million CNY [3] Reason for Price Adjustment - The adjustment was necessary due to the cash dividend distribution of 1.3 CNY per share, which was approved in the board meetings and the annual shareholders' meeting, impacting the repurchase price [4] Repurchase Quantity Estimation - With the adjusted upper limit of 176.73 CNY per share, the estimated number of shares that could be repurchased ranges from approximately 565,834 shares (0.46% of total shares) to 1,131,669 shares (0.92% of total shares), depending on the total repurchase fund utilized [5] Other Conditions - All other aspects of the share repurchase plan remain unchanged, and the company will adhere to relevant regulations during the repurchase period [6]